FRMM
Forum MarketsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
The balance sheet improved meaningfully by quarter-end, and the RWA tokenization / ETH-yield strategy could create option value if management turns the pivot into repeatable assets and cash flow.
Posture
Defensive
Lead driver
Momentum
What changed
Next scheduled catalyst: earnings 2026-07-21.
What can break
Management explicitly warns that failure to commercialize RWA plans could leave the company vulnerable to shell-company style risk again.
Momentum
78
Value
41
Sentiment
1
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.40 · Bull $5.20 · Bear $1.90
Earnings
2026-07-21
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-20 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $10.00
Why
Momentum78 · Δ7d +21.6
Value41 · Δ7d +0.0
Sentiment1 · Δ7d +1.6
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
78
26% active weight
Current posture
7d trendFlat
Δ7d
+21.6
Δ21d
+10.9
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
1
34% active weight
Current posture
7d trendImproving
Δ7d
+1.6
Δ21d
-2.4
Why this grade
Composite grade F. Momentum 78.1 / Value 41.1 / Sentiment 1.1
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$80.05M
Beta
1.19
Shares Out
13.21M
P/E (TTM) · Derived
-0.1
P/S (TTM)
24.79
P/FCF (TTM) · Derived
-1.11
Rev YoY
-
EPS YoY
-46.5%
Gross Margin
-
Op Margin
-5445.2%
Net Debt
$48.68M
Current Ratio
6.19
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology